Pliant Therapeutics, Inc., a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). Patients currently enrolled in BEACON-IPF will remain in the trial.
Enrollment and dosing have been paused while data is reviewed to understand the DSMB’s rationale for their recommendation. Blinding of the study will be maintained to preserve trial integrity. The company has informed BEACON-IPF clinical trial investigators and is in the process of informing global regulatory authorities.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avß6 and avß1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF.
